Skip to content
Open access

Event-Driven Intensification and Persistent Therapeutic Inertia in LDL-C Management Among 1,033,703 Patients With ASCVD

Aug 2026 · JACC: Advances · Vol 5 · 0 citations · 25 references
Medicine

TL;DR

In ASCVD patients, LDL-C levels plateau well above guideline targets following an initial decline, and proactive, system-level monitoring and timely intervention are urgently needed to reduce cumulative above-goal LDL-C exposure.

Abstract

Background Long-term control of low-density lipoprotein cholesterol (LDL-C) is key to reducing the risk of atherosclerotic cardiovascular disease (ASCVD), yet most large-scale evaluations have been cross-sectional. Objectives This study aimed to characterize the long-term trends in LDL-C among patients with ASCVD and to identify factors associated with reaching LDL-C goals. Methods Using data from the cvMOBIUS-2 (Cardiovascular Multicenter Observational Investigation of Lipid Care in the United States-2) registry, which pools electronic health record data from 17 U.S. health systems, we identified adults with ASCVD and a baseline LDL-C ≥70 mg/dL. We used generalized estimating equations to model LDL-C trends and multivariable logistic regression to identify clinical factors associated with: 1) achieving an LDL-C <70 mg/dL at 12 months; and 2) therapeutic intensification, defined as statin initiation/increase or nonstatin addition, within 1 year. Results Among 1,033,703 patients (median age 67.9 years; 49.2% women) with a median follow-up of 2.2 years (IQR: 1.1-3.8 years), LDL-C demonstrated a “drop-and-plateau” pattern: following an initial decline, mean LDL-C stalled well above 80 mg/dL and remained elevated throughout the remaining follow-up. A recurrent ASCVD event was strongly associated with both achieving LDL-C <70 mg/dL (OR: 2.18; 95% CI: 1.98-2.40) and therapeutic intensification (OR: 2.77; 95% CI: 2.34-3.27). Conversely, peripheral artery disease was associated with lower odds of goal attainment (OR: 0.70; 95% CI: 0.68-0.72) and intensification (OR: 0.73; 95% CI: 0.70-0.75). Conclusions In ASCVD patients, LDL-C levels plateau well above guideline targets following an initial decline. Because lipid management remains predominantly event-driven, proactive, system-level monitoring and timely intervention are urgently needed to reduce cumulative above-goal LDL-C exposure.

Read PDF

Similar papers

Open access Sep 2026

LDL-C Target Attainment and Treatment Gaps Six Months After Acute Coronary Syndrome: insights from the CALLINICUS-Hellas registry.

BACKGROUND Low-density lipoprotein cholesterol (LDL-C) reduction is the cornerstone of secondary prevention after acute coronary syndrome (ACS). Despite potent lipid-lowering therapies (LLTs), a therapeutic gap persists. We aimed to evaluate LDL-C target attainment according to the 2019 ESC/EAS guidelines, identify pre...

L. Rallidis, D. Tsamoulis, Despoina-Rafailia Benetou et al. · 0 citations
Open access Sep 2026

Predicting LDL-cholesterol reduction variability on statin-ezetimibe therapy: insights from "Jena auf Ziel".

Upfront dual therapy with atorvastatin (80 mg) and ezetimibe (10 mg) achieved robust LDL‑C reduction with low interindividual variability in treatment-naive individuals, which supports current guideline recommendations for immediate combination therapy in very high-risk patients, irrespective of their baseline metaboli...

U. Makhmudova, D. Lütjohann, F. Haertel et al. · 0 citations
Open access Sep 2026

Contemporary lipid management and achievement of LDL-C targets after acute myocardial infarction in Japan: Insights from the K-ACTIVE registry.

BACKGROUND There are limited data on contemporary lipid management practices after acute myocardial infarction (AMI) in Japan and on factors associated with achieving the low-density lipoprotein cholesterol (LDL-C) target recommended by current Japanese guidelines (<70 mg/dL). METHODS We retrospectively analyzed 2984...

N. Kamioka, Yohei Ohno, Y. Ikari et al. · 0 citations
Oct 2026

A-035 Closing the Gap in Lipid Management: Modified Sampson Equation Reduces Missed Treatment Opportunities Compared to Extended Martin at Low LDL-C

Low-density lipoprotein cholesterol (LDL-C) is associated with atherosclerotic cardiovascular disease (ASCVD) and is a target for therapy. Calculated LDL-C equations show variable accuracy compared to the gold standard beta-quantification (BQ), particularly at lower LDL-C concentrations commonly used as treatment...

Maureen Sampson, R. Zubirán, Mingsum S. Lee et al. · 0 citations
Open access Sep 2026

Gaps in lipid management among high-risk patients without prior MI or stroke: the VESALIUS-REAL global study.

Most patients at high CV risk were not optimally managed, with low rates of LLT initiation, treatment intensification, LDL-C monitoring, and LDL-C goal attainment across 11 databases, highlighting a substantial unmet clinical need for improved guideline-based lipid management to prevent first major CV events in high-ri...

Q. Chan, J. Cegla, U. Laufs et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.